Myfortic (Mycophenolic Acid)

Mycophenolic acid inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for the synthesis of guanosine nucleotides. This inhibition limits the proliferation of T‑ and B‑lymphocytes, thereby dampening the immune response that can attack a transplanted organ.

The dosage of Myfortic is individualized by the prescribing clinician based on the type of transplant, patient weight, renal function and concurrent immunosuppressants. Patients should follow the exact regimen provided by their healthcare professional.

Safety data for mycophenolic acid in pregnancy and lactation are limited. It is generally advised that women of child‑bearing potential discuss potential risks with their physician and use effective contraception. Breastfeeding decisions should also be made in consultation with a healthcare provider.

To request Myfortic, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolic acid) belongs to the antimetabolite class, whereas alternatives such as azathioprine are purine analogues and calcineurin inhibitors like cyclosporine act on different pathways. Myfortic offers a distinct mechanism targeting lymphocyte proliferation, which can be advantageous in combination regimens but may have a different side‑effect profile.

Myfortic should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency.

Myfortic is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact timing and frequency are determined by the treating physician based on the individual’s therapeutic plan.

Serious risks include severe infections, leukopenia, anemia, hepatic dysfunction, and rare but potentially fatal conditions such as progressive multifocal leukoencephalopathy. Patients should be monitored regularly for these complications and report any concerning symptoms promptly.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any of its excipients, those with active uncontrolled infections, and individuals who are pregnant unless the potential benefit justifies the risk. It should also be used with caution in patients with severe renal or hepatic impairment.